This review highlights circulating tumor DNA as an increasingly useful minimally invasive biomarker for detecting molecular residual disease, monitoring treatment response/resistance, and identifying actionable genomic alterations—often preceding radiographic progression by months–though the optimal timing, testing frequency, and management of ctDNA-positive patients without radiographic disease remain unsettled. |
